A Randomized, Double-Blind, Placebo-Controlled Study on Analgesic and CNS Effects of Morphine and Fluvoxamine in Chronic Pain in Healthy Subjects

The primary objective of this study is to evaluate the **analgesic effects** and central nervous system (CNS) effects of **morphine** and **fluvoxamine** in healthy subjects. This investigation is clinically relevant as it aims to understand the efficacy and safety profile of these medications in managing **chronic pain**, which is a prevalent and challenging condition to treat effectively. The study employs a randomized, double-blind, double dummy, placebo-controlled, four-way cross-over design to ensure robust and reliable results.

The clinical trial involves participants diagnosed with **chronic pain**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been disclosed. The trial population was selected without any specific emphasis on vulnerable groups, ensuring a broad representation of individuals experiencing chronic pain.

The clinical trial is designed as a **randomized**, **double-blind**, double dummy, placebo-controlled, four-way cross-over study. It aims to investigate the analgesic effects and central nervous system (CNS) effects of morphine and fluvoxamine in healthy subjects. The trial is focused on the medical condition of **chronic pain** and is categorized as a Phase 3 study. The estimated recruitment start date is October 23, 2023, with an anticipated end date of May 31, 2024, indicating an overall trial duration of approximately seven months.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different treatment arms. The study will include multiple follow-up visits to monitor the effects of the interventions and ensure participant safety. These visits will be conducted in a double-blind manner, meaning neither the participants nor the investigators will know which treatment is being administered at any given time. The end-of-study visit will conclude the trial, where final assessments will be conducted to evaluate the primary and secondary endpoints.

The expected length of participant involvement will span the entire duration of the trial, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design ensures rigorous control and monitoring to maintain the integrity of the data collected and the safety of the participants throughout the study period.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on October 23, 2023, with an estimated end date of May 31, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact on the specified medical condition, utilizing appropriate clinical methodologies and tools as per standard Phase 3 trial protocols.